Table 1.
Characteristics of the populations.
| Variable | n = 42 |
|---|---|
| Age, Median (IQR) | 34.5 (33.0–39.0) |
| Education, n (%) | |
| High school diploma | 4 (9.5) |
| Degree | 33 (78.6) |
| Postgraduate | 1 (2.4) |
| PhD | 4 (9.5) |
| Occupation, n (%) | |
| Medical doctor | 16 (38.0) |
| Nurse-midwife | 8 (19.1) |
| Teacher | 8 (19.1) |
| Other | 10 (23.8) |
| Comorbidity, n (%) | 7 (16.7) |
| Basedow disease | 1 (2.4) |
| Behcet disease | 1 (2.4) |
| Hypothyroidism | 2 (4.8) |
| Hashimoto’s thyroiditis | 3 (7.2) |
| Drugs in the last 10 days, n (%) | 6 (14.3) |
| Antihistamines | 2 (4.8) |
| Anti-inflammatory | 1 (2.4) |
| Other | 3 (7.2) |
| Previous COVID-19 infection, n (%) | 2 (4.8) |
| Vaccine type | |
| Pfizer/BioNtech | 35 (83.3) |
| Astrazeneca | 4 (9.5) |
| Moderna | 2 (4.8) |
| Mixed | 1 (2.4) |
| Days between collection and the 2nd dose of vaccine, median (IQR) | 22 (16–46) |
| At least one adverse event, n (%) | 20 (47.6) |
| Injection site pain | 11 (26.2) |
| Headache | 4 (9.5) |
| Pyrexia | 9 (45.0) |
| Myalgia | 9 (45.0) |
| Ostealgia | 2 (4.8) |
| Arthralgia | 2 (4.8) |
| Allergic reaction | 0 (0.0) |
| Asthenia | 12 (28.6) |
| Chills | 3 (7.2) |
| Vaccine influence on breastfeeding, n (%) | 8 (19.1) |
| Number of milk feed, median (IQR) | 5 (4–7) |
| OD milk, median (IQR) | 0.8 (0.7–1.2) |
| OD serum, median (IQR) | 0.3 (0.2–0.8) |
| Index milk, median (IQR) | 0.6 (0.5–0.6) |
| Index serum, median (IQR) | 0.2 (0.1–0.5) |
| New-born age in months, median (IQR) | 11.5 (8–17) |
| Days between delivery and vaccine, median (IQR) | 319.5 (111.0–486.0) |
| Adverse events in the child within 7 days after the vaccine | |
| Restlessness | 1 (2.4) |
| Cold | 1 (2.4) |
| Skin rash | 1 (2.4) |
| Infant’s attendance of kindergarten, n (%) | 7 (16.7) |